Results 61 to 70 of about 926 (182)

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis

, 2021
Introduction: Patients with primary biliary cholangitis (PBC) without biochemical response to ursodeoxycholic acid (UDCA) are at increased risk of liver-related mortality.
Parmar, Deven, Payan-Olivas, Ramon, Deven Parmar, Farheen Shaikh, Ramon Payan-Olivas, González-Huezo, Ma Saraí, Shaikh, Farheen, Linda E. Muñoz-Espinosa, Pio Cruz-Lopez, Jose L., Ma Saraí González-Huezo, Vuppalanchi, Raj, Jose L. Pio Cruz-Lopez, Raj Vuppalanchi, Muñoz-Espinosa, Linda E.   +13 more
core   +1 more source

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales

Journal of Translational Autoimmunity, 2023
Introduction: Primary biliary cholangitis (PBC) is an autoimmune liver disease involving the small intrahepatic bile ducts; when untreated or undertreated, it may evolve to liver fibrosis and cirrhosis. Ursodeoxycholic Acid (UDCA) is the standard of care
Francesca Colapietro, M. Eric Gershwin, Ana Lleo   +2 more
doaj   +1 more source

Diabetic Dyslipidemia - Role of Saroglitazar

Medicinal Chemistry, 2014
‘Diabetic dyslipidemia’ (combination of raised triglyceride levels, raised small-dense Low-density lipoprotein particles and low high-density lipoprotein cholesterol levels) is the most prominent risk factor of atherosclerosis and cardiovascular disease.
openaire   +1 more source

From Crisis to Diagnosis: A Case of Hypertriglyceridemic Pancreatitis as the First Clinical Presentation of Type 1 Diabetes [PDF]

Journal of Clinical and Diagnostic Research
Acute Pancreatitis (AP) is a prevalent and rapidly progressive inflammatory disorder of the pancreas, often presenting with abdominal pain and elevated serum pancreatic enzymes.
Subashini Vadivel, Sheetal Nandha Kishore, Jagannath S Dhadwad, Janvi Panchal   +3 more
doaj   +1 more source

Fatty liver - Current and future treatment: A narrative review

Apollo Medicine, 2021
A holistic approach is required for managing patients with nonalcoholic fatty liver disease (NAFLD). Lifestyle interventions and medical management of metabolic risk factors currently form the cornerstone of NAFLD management.
Arka De, Ajay Duseja
doaj   +1 more source

Alcohol‐Related Liver Disease and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 6, Issue 12, December 2025.
Alcohol‐related (ALD) and metabolic dysfunction‐associated (MASLD) steatotic liver disease, while initiated by distinct etiologies (ethanol vs. metabolic stress), converge on shared core pathogenic pathways that drive progression. These include dysregulated lipid metabolism, programmed cell death, cellular senescence, gut dysbiosis, and immune ...
Yupin Tan, Yirui Hu, Ye Yang, Huikuan Chu   +3 more
wiley   +1 more source

A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL [PDF]

Journal of Clinical and Experimental Hepatology
Bilal Ahmad Mir, Brij Sharma, Vishal Bodh   +2 more
exaly   +2 more sources

Effect of saroglitazar in South Indian patients with diabetic dyslipidemia uncontrolled on a moderate-intensity statin and the association of PPAR α and γ gene polymorphisms with its response

, 2023
Background: Diabetic dyslipidemia is associated with atherosclerosis risk factors and cardiovascular disease. Saroglitazar is a dual PPAR α and γ agonist approved initially for diabetic dyslipidemia and later for managing non-alcoholic steatohepatitis ...
Selvarajan, Sandhiya, Isaac J. Bage, Sadishkumar Kamalanathan, Mathaiyan, Jayanthi, Naik, Dukhabandhu, Sahoo, Jayaprakash, Sandhiya Selvarajan, Jayanthi Mathaiyan, Kamalanathan, Sadishkumar, Dukhabandhu Naik, Jayaprakash Sahoo, Bage, Isaac J.   +11 more
core   +2 more sources

The Efficacy and Safety of Seladelpar for Primary Biliary Cholangitis: A Systematic Review and Meta‐Analysis

JGH Open, Volume 9, Issue 9, September 2025.
ABSTRACT Background and Objective Seladelpar is an oral, once‐daily medication that improves cholestasis through its selective peroxisome proliferator‐activated receptor (PPAR‐δ) agonism. It shows promising efficacy in treating primary biliary cholangitis (PBC) patients.
Mohamed Abuelazm, Saqr Alsakarneh, Mohammad Tanashat, AlMothana Manasrah, Ahmed A. Ibrahim, Sandesh Parajuli, Hatem Eltaly, Ahmed Mazen Amin   +7 more
wiley   +1 more source

Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

, 2023
Saroglitazar is a novel medication for dyslipidemia, but its specific effects remain unclear. Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of saroglitazar for managing dyslipidemia.
Antonio da Silva Menezes Junior, Izadora Caiado Oliveira, Ricardo Figueiredo Paro Piai, Vinícius Martins Rodrigues Oliveira, Ana Júlia Prego Santana, Davi Peixoto Craveiro Carvalho, André Maroccolo de Sousa, Arthur Marot de Paiva, Fernando Henrique Matos, Gabriel Baêta Branquinho Reis   +9 more
core   +1 more source